DivestmentMay 11, 2026, 05:23 PM
MacroGenics Sells Manufacturing Ops to Bora for $122.5M
AI Summary
MacroGenics, Inc. announced a definitive agreement to sell its good manufacturing practice (GMP) drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. for an upfront payment of $122.5 million. This strategic move aims to provide non-dilutive capital to accelerate MacroGenics' pipeline development and allow the company to focus on its core innovative therapeutics. The deal includes the transfer of the Maryland manufacturing site, CDMO operations, and approximately 140 employees to Bora, while MacroGenics secures a supply arrangement for its future needs.
Key Highlights
- MacroGenics to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals.
- MacroGenics will receive an upfront payment of $122.5 million from Bora.
- The transaction includes the transfer of the Rockville, MD manufacturing site (11,000 liters capacity) and Frederick, MD warehouse.
- Approximately 140 MacroGenics employees are expected to be hired by Bora.
- MacroGenics will maintain a supply arrangement with Bora for its internal pipeline needs.
- The transaction is expected to close in the third quarter of 2026.